Profile data is unavailable for this security.
About the company
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.
- Revenue in SEK (TTM)1.37bn
- Net income in SEK401.72m
- Incorporated1990
- Employees220.00
- LocationBiogaia ABKungsbroplan 3STOCKHOLM 112 27SwedenSWE
- Phone+46 855529300
- Fax+46 855529301
- Websitehttps://sv.biogaia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Probi AB | 642.71m | 13.70m | 3.19bn | 162.00 | 232.84 | 2.25 | 28.19 | 4.96 | 1.20 | 1.20 | 56.41 | 124.20 | 0.4045 | 3.25 | 5.91 | 4,016,925.00 | 0.8624 | 4.64 | 0.9144 | 4.98 | 32.88 | 42.04 | 2.13 | 9.83 | 4.69 | -- | 0.0591 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
| Flerie AB | 108.34m | -56.48m | 3.75bn | 7.00 | -- | 1.08 | -- | 34.62 | -10.37 | -10.37 | 20.28 | 44.30 | 0.3559 | -- | -- | 15,477,000.00 | -18.55 | -37.64 | -21.24 | -41.14 | -46.98 | -450.51 | -52.13 | -454.62 | -- | -- | 0.0086 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
| Swedencare AB (publ) | 2.41bn | 71.50m | 8.43bn | 552.00 | 117.88 | 1.09 | 21.98 | 3.49 | 0.4505 | 0.4505 | 15.21 | 48.80 | 0.2412 | 2.35 | 9.52 | 4,966,461.00 | 0.7144 | 1.38 | 0.7361 | 1.43 | 55.64 | 55.34 | 2.96 | 5.10 | 1.82 | 2.21 | 0.1746 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| Calliditas Therapeutics AB | 1.31bn | -524.82m | 12.36bn | 219.00 | -- | 92.11 | -- | 9.43 | -9.78 | -9.78 | 24.43 | 2.24 | 0.7541 | 3.16 | 8.97 | 6,723,169.00 | -30.19 | -26.46 | -38.05 | -30.27 | 95.01 | -- | -40.03 | -76.59 | 2.62 | -3.99 | 0.8943 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| BioGaia AB | 1.37bn | 401.72m | 12.44bn | 220.00 | 32.15 | 8.20 | 29.21 | 9.09 | 3.98 | 3.98 | 13.56 | 15.60 | 0.6749 | -- | -- | 6,520,886.00 | 19.80 | 15.47 | 22.19 | 16.93 | 73.84 | 73.30 | 29.34 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Vimian Group AB | 3.91bn | 92.72m | 17.90bn | 1.10k | 173.80 | 2.58 | 36.64 | 4.57 | 0.1992 | 0.1992 | 8.35 | 13.40 | 0.3354 | 2.83 | 5.69 | 3,556,942.00 | 0.867 | -- | 1.01 | -- | 47.48 | -- | 2.59 | -- | 1.19 | 2.81 | 0.3729 | -- | 17.92 | -- | 245.95 | -- | -- | -- |
| Bonesupport Holding AB | 735.16m | 288.78m | 19.65bn | 127.00 | 68.31 | 31.68 | 65.65 | 26.73 | 4.38 | 4.38 | 11.13 | 9.44 | 1.30 | 0.6001 | 4.88 | 7,001,534.00 | 51.17 | -9.08 | 62.05 | -11.28 | 92.22 | 90.25 | 39.28 | -11.65 | 3.07 | -- | 0.0239 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Bavarian Nordic A/S | 10.40bn | 1.54bn | 23.32bn | 1.38k | 14.83 | 1.46 | 9.45 | 2.24 | 12.86 | 12.86 | 86.59 | 130.35 | 0.4956 | 1.74 | 9.32 | 4,816,359.00 | 7.35 | 1.21 | 8.92 | 1.48 | 60.90 | 53.72 | 14.82 | 4.06 | 1.03 | -- | 0.0427 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Camurus AB | 1.59bn | 223.25m | 38.70bn | 228.00 | 174.01 | 13.22 | 162.57 | 24.29 | 3.79 | 3.79 | 27.51 | 49.94 | 0.6122 | 1.09 | 4.86 | 7,480,770.00 | 8.58 | -1.13 | 10.10 | -1.41 | 92.01 | 90.05 | 14.01 | -1.63 | 7.11 | -- | 0.0071 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 7.74bn | 868.96m | 48.46bn | 2.83k | 61.31 | 7.21 | 36.33 | 6.26 | 2.49 | 2.49 | 21.93 | 21.19 | 0.752 | 1.29 | 5.81 | 1,749,646.00 | 8.45 | 3.50 | 10.36 | 4.37 | 63.25 | 60.66 | 11.23 | 5.07 | 1.23 | 50.27 | 0.0995 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
Data as of Jul 25 2024. Currency figures normalised to Biogaia AB's reporting currency: Swedish Krona SEK
27.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2023 | 7.75m | 7.97% |
| Premier Fund Managers Ltd.as of 31 Dec 2023 | 4.31m | 4.43% |
| Teknik Innovation Norden Fonder ABas of 31 Dec 2023 | 3.00m | 3.08% |
| Tredje AP-fondenas of 31 Dec 2023 | 2.38m | 2.45% |
| Juno Investment Partnersas of 31 Dec 2023 | 1.98m | 2.03% |
| Handelsbanken Fonder ABas of 31 Dec 2023 | 1.94m | 1.99% |
| AMF Fonder ABas of 31 Dec 2023 | 1.86m | 1.91% |
| Montanaro Asset Management Ltd.as of 31 May 2024 | 1.33m | 1.37% |
| Allianz Global Investors GmbHas of 30 Apr 2024 | 1.26m | 1.30% |
| L�nsf�rs�kringar Fondf�rvaltning ABas of 30 Jun 2024 | 1.21m | 1.24% |
More ▼
Data from 31 Dec 2022 - 30 Jun 2024Source: FactSet Research Systems Inc.
